Medical Procurement of Ukraine, the state-owned enterprise responsible for pharmaceutical procurement, has confirmed that no businesses have been granted permission for parallel import of medicinal products. The parallel import mechanism, which aims to increase the availability of essential medications, has not yet started operating. This decision comes as Ukraine continues to grapple with challenges in ensuring a steady supply of medical supplies, particularly in light of ongoing conflicts and global supply chain disruptions.
The statement was released by the SOE through Interfax-Ukraine, a state news agency. Officials emphasized that the government is carefully evaluating the potential benefits and risks of implementing the parallel import mechanism. While the mechanism could potentially lower drug prices and improve access to medicines, there are concerns about quality control and regulatory compliance. The government has not provided a timeline for when the mechanism might be activated, leaving pharmaceutical companies and healthcare providers in uncertainty.
Analysts suggest that the delay in launching the parallel import initiative may be due to bureaucratic hurdles and the need to establish robust regulatory frameworks. The situation highlights the complexities of balancing cost efficiency with patient safety in the pharmaceutical supply chain. As Ukraine works to strengthen its healthcare infrastructure, the activation of the parallel import mechanism remains a critical but pending step in addressing drug shortages and ensuring equitable access to medicines for all citizens.